Previous 10 | Next 10 |
Oncternal Therapeutics ( NASDAQ: ONCT ) said on Tuesday it had begun a Phase 3 global registrational study of zilovertamab (ZILO-301) to treat patients with relapsed/refractory mantle cell lymphoma. The Company received its first Institutional Review Board approval for...
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (...
SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Con...
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment...
Summary Today, we are circling back on Oncternal Therapeutics, Inc. for the first time since last October. Despite advancing its pipeline and strong analyst support, the stock currently sells for less than the cash on the company's balance sheet. An investment analysis follows...
Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Tran...
Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Conference Call August 9, 2022, 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call P...
Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q2 GAAP EPS of -$0.23 beats by $0.02 . Revenue of $0.2M (-77.3% Y/Y) misses by $0.26M . Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equ...
Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to historical single agent ibrutinib data and support moving into Phase 3 Study ZILO-301 Interim data from p53-mutated CLL patients in t...
3 Ways That World Events Cause Penny Stocks Movement When it comes to buying and selling penny stocks, world events are likely the main cause of market movement. Wars, natural disasters, and other geo-political, and economic events can all have a profound effect on both penny stocks a...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...